Literature DB >> 21696927

Seventeen-year clinical outcome of schizophrenia in Bali.

T Kurihara1, M Kato, R Reverger, I G R Tirta.   

Abstract

OBJECTIVE: To examine the 17-year clinical outcome of schizophrenia and its predictors in Bali.
METHODS: Subjects were 59 consecutively admitted first-episode schizophrenia patients. Their clinical outcome was evaluated by standardized symptomatic remission criteria based on Positive and Negative Syndrome Scale (PANSS) scores and operational functional remission criteria at 17-year follow-up. The standardized mortality ratio (SMR) over 17 years was also calculated as another index of clinical outcome.
RESULTS: Among these 59 patients, 43 (72.9%) could be followed-up, 15 (25.4%) had died, and one (1.7%) was alive but refused to participate in the study. Combined remission (i.e. symptomatic and functional remission) was achieved in 14 patients (23.7% of original sample). Duration of untreated psychosis (DUP) was a significant baseline predictor of combined remission. Mean age at death of deceased subjects was 35.7, and SMR was 4.85 (95% CI: 2.4-7.3), indicating that deaths were premature. Longer DUP was associated with excess mortality.
CONCLUSIONS: The long-term outcome of schizophrenia in Bali was heterogeneous, demonstrating that a quarter achieved combined remission, half were in nonremission, and a quarter had died at 17-year follow-up. DUP was a significant predictor both for combined remission and mortality.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696927     DOI: 10.1016/j.eurpsy.2011.04.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

1.  Sexual Risk Behavior, Sexual Violence, and HIV in Persons With Severe Mental Illness in Uganda: Hospital-Based Cross-Sectional Study and National Comparison Data.

Authors:  Patric Lundberg; Noeline Nakasujja; Seggane Musisi; Anna Ekéus Thorson; Elizabeth Cantor-Graae; Peter Allebeck
Journal:  Am J Public Health       Date:  2015-04-16       Impact factor: 9.308

2.  Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.

Authors:  Masuma Pervin Mishu; Eleonora Uphoff; Faiza Aslam; Sharad Philip; Judy Wright; Nilesh Tirbhowan; Ramzi A Ajjan; Zunayed Al Azdi; Brendon Stubbs; Rachel Churchill; Najma Siddiqi
Journal:  Cochrane Database Syst Rev       Date:  2021-02-16

3.  Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study.

Authors:  C Morgan; J Lappin; M Heslin; K Donoghue; B Lomas; U Reininghaus; A Onyejiaka; T Croudace; P B Jones; R M Murray; P Fearon; G A Doody; P Dazzan
Journal:  Psychol Med       Date:  2014-02-26       Impact factor: 7.723

Review 4.  Schizophrenia outcomes in the 21st century: A systematic review.

Authors:  Peter Huxley; Anne Krayer; Rob Poole; Louise Prendergast; Sanjaya Aryal; Richard Warner
Journal:  Brain Behav       Date:  2021-05-15       Impact factor: 2.708

5.  Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment?

Authors:  Zhang Cheng; Yanbo Yuan; Xue Han; Lei Yang; Xin Zeng; Fude Yang; Zheng Lu; Chuanyue Wang; Hong Deng; Jingping Zhao; Xin Yu
Journal:  Front Psychiatry       Date:  2020-06-19       Impact factor: 4.157

Review 6.  Reducing the Mortality Gap in People With Severe Mental Disorders: The Role of Lifestyle Psychosocial Interventions.

Authors:  Sarah Barber; Graham Thornicroft
Journal:  Front Psychiatry       Date:  2018-09-28       Impact factor: 4.157

7.  Prevalence of physical health conditions and health risk behaviours in people with severe mental illness in South Asia: protocol for a cross-sectional study (IMPACT SMI survey).

Authors:  Gerardo A Zavala; Krishna Prasad-Muliyala; Faiza Aslam; Deepa Barua; Asiful Haidar; Catherine Hewitt; Rumana Huque; Sonia Mansoor; Pratima Murthy; Asad T Nizami; Najma Siddiqi; Siham Sikander; Kamran Siddiqi; Jan Rasmus Boehnke
Journal:  BMJ Open       Date:  2020-10-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.